Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Texas Southwestern Medical Center
With
Celgene
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with tumors adjacent to a vertebral body are eligible as long as all gross disease can be encompassed in the radiation boost field. The boost volume must be limited to \< 50% of the ipsilateral lung volume.
Patients with Zubrod performance status 0-1
Adequate hematologic function
FEV1 with ≥ 1200 cc or ≥ 50% predicted
You may not be if
Prior systemic chemotherapy (for lung cancer) and/or thoracic/neck radiotherapy for any reason and/or surgical resection of present cancer
Exudative, bloody, or cytologically malignant effusions
Prior therapy with any molecular targeted drugs (for lung cancer)
Active pulmonary infection not responsive to conventional antibiotics
Clinically significant cardiovascular event (e.g. myocardial infarction, superior vena cava syndrome (SVC), New York Heart Association (NYHA) classification of heart disease \>2 (see Appendix B) within 3 months before entry; or presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia.
Patients with \> grade 1 neuropathy
Clareo Health | Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
